Abstract
Plasma total cysteine (tCys) is strongly associated with fat mass in humans. Mesna lowers plasma tCys in a dose-dependent manner, but it is not known whether it interferes with metabolism of other amino acids or protein. In this Phase-1 study, we show that a single dose of mesna administered at 400, 800, 1200 or 1600 mg to 6–7 individuals per dose only slightly affects amino acid profiles, with increases in plasma valine across dose levels. There were no effects of mesna on 3-methylhistidine, a marker of protein breakdown.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00726-024-03398-2.
Keywords: Mesna, Total cysteine, Overweight, Obesity, Amino acid profile, 3-methylhistidine
Introduction
Plasma concentrations of total cysteine (tCys) are strongly and linearly associated with overweight and obesity (Elshorbagy et al. 2008, 2012). Dietary restriction of cysteine and its precursor, methionine, leads to significant improvements in body composition of mice (Cooke et al. 2020; Hasek et al. 2013; Malloy et al. 2006, 2013; Nichenametla et al. 2022). Furthermore, in a recent randomized controlled trial (RCT), we substantiated that implementing a dietary restriction of cysteine led to a significantly greater weight loss among human participants (Olsen et al. 2024). This link between cysteine and obesity has motivated interest in the therapeutic potential of pharmacologically lowering plasma tCys concentrations to lower fat mass and obesity in humans. Cysteine-lowering can be achieved with mesna – sodium-2-mercaptoethane sulfonate – a pharmacological thiol agent that forms disulfide bonds with cysteine in the circulation, leading to increased urinary excretion (Lauterburg et al. 1994; Stofer-Vogel et al. 1993; Urquhart et al. 2007). We have previously shown that a single oral dose of mesna up to 1600 mg was well-tolerated and significantly reduced plasma concentrations of tCys (up to 52% reduction at nadir) for up to 12 h post-dose (Vinknes et al. 2023).
Although restricting cysteine availability through the diet distinctly improves body composition in rodents (Dong et al. 2018), it slows rates of protein synthesis in the liver and skeletal muscle (Martinez et al. 2022; Nichenametla et al. 2018), and alters the plasma amino acid pool (Nichenametla et al. 2022). This effect may be due to redirection of amino acids to other metabolic processes, including the tricarboxylic acid (TCA) cycle (Gao et al. 2019), and dietary cysteine restriction may therefore contribute to the observations of lower lean, bone and skeletal muscle mass as compared to controls (Ables et al. 2012; Cooke and Ables 2023; Cooke et al. 2020).
As opposed to dietary cysteine restriction, pharmacological reduction of cysteine using mesna reduce fat mass accumulation but not lean mass accumulation in mice (Vinknes et al. 2023). Taken together with previous evidence (Martinez et al. 2022; Nichenametla et al. 2018; Nichenametla et al. 2022), these demonstrations indicate that the amino acid pool available for protein synthesis may be affected differently in pharmacologic compared to dietary manipulation of cysteine. However, there is no evidence on the effect of mesna on the plasma amino acid pool and/or protein breakdown in humans. To explore this, we utilized data from our previous dose-escalation trial with mesna in humans with overweight and obesity, and investigated whether a single oral dose of mesna (400, 800, 1200 and 1600 mg/d) influenced plasma and urinary excretion of 20 amino acids and 3-methylhistidine, a marker of protein breakdown.
Methods
The present data are from a phase-1, non-randomized single ascending dose study in healthy volunteer men with overweight and obesity. Details on the study protocol, study design, blood sampling, and main results have been published elsewhere (Vinknes et al. 2023). Briefly, 17 men were assigned to receive 400 mg (n = 7), 800 mg (n = 6), 1200 mg (n = 6) and 1600 mg (n = 6) of oral mesna. Blood samples were taken at baseline and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose into EDTA-lined tubes. Twenty-four-hour urine was collected as described previously (Vinknes et al. 2023). Blood and urine were stored at − 80 ℃ until analysis. Plasma and urine amino acid profiles, and 3-methyl-histidine were measured using liquid chromatography-tandem mass spectrometry using previously published methods (Turner et al. 2023). Measured analytes included alanine, arginine, asparagine, aspartate (plasma only), glutamate, glutamine, glycine, histidine, isoleucine, leucine, lysine, ornithine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine and valine. All study participants gave written informed consent. The study was performed according to the Declaration of Helsinki, and approved by Regional Ethics Committee South-East (Ref no. 87266).
Area under the plasma concentration versus time curve (AUC) was calculated for each amino acid using the trapezoidal method. Ptrend was calculated using linear regression in separate models for each amino acid, where the AUC was the dependent variable and the dose was the independent variable. P-values < 0.05 were considered statistically significant.
Results
Baseline characteristics
Baseline characteristics of the participants has been published previously (Vinknes et al. 2023). Briefly, n = 17 men with a mean (SD) age of 43.5 (8.4) years and BMI of 32.7 (3.0) kg/m2 participated in the present study. Baseline amino acid profiles according to dose level can be viewed in Supplemental Table S1.
Plasma and urinary excretion of amino acids by dose level
The AUC for valine increased significantly with increasing dose levels (β = 110 µmol×h/L, 95% CI: 14.6, 205, ptrend = 0.03). Similar responses were observed for isoleucine and tryptophan, but these findings did not reach statistical significance (ptrend < 0.10, Table 1). No effects of mesna were observed on plasma levels of 3-methylhistidine. Furthermore, no effects of escalating mesna dosing were observed on 24-h urinary excretion of amino acids or 3-methylhistidine (Supplemental Table S2).
Table 1.
Mean (standard deviation) area under the curve of plasma amino acid concentrations according to mesna dosing
| 400 mg | 800 mg | 1200 mg | 1600 mg | β (95% CI) |
P trend | |
|---|---|---|---|---|---|---|
| Amino acid, µmol×h/L | ||||||
| Alanine | 4530 (603) | 4000 (794) | 4520 (673) | 4500 (493) |
33.2 (-207, 274) |
0.78 |
| Arginine | 1130 (172) | 1050 (158) | 1080 (70.7) | 1140 (146) |
5.45 (-46.4, 57.3) |
0.83 |
| Asparagine | 445 (59.6) | 429 (84.9) | 530 (61.8) | 452 (97.5) |
12.4 (-17.7, 42.5) |
0.40 |
| Aspartate | 56.7 (28.9) | 43.8 (11.6) | 50.1 (8.1) | 51.4 (8.44) |
-1.20 (-7.5, 5.09) |
0.70 |
| Glutamate | 758 (274) | 563 (172) | 641 (214) | 745 (123) |
0.07 (-78.4, 78.5) |
1.00 |
| Glutamine | 6800 (874) | 6700 (418) | 7320 (446) | 7160 (638) |
165 (-65.1, 396) |
0.15 |
| Glycine | 2610 (411) | 2750 (580) | 2650 (541) | 2540 (556) |
-28.6 (-212, 155) |
0.75 |
| Histidine | 1050 (94) | 1030 (90.9) | 1080 (53.9) | 1040 (63.8) |
1.64 (-26.5, 29.8) |
0.91 |
| Isoleucine | 924 (120) | 1030 (126) | 921 (119) | 1100 (162) |
42.5 (-8.44, 93.4) |
0.098 |
| Leucine | 1660 (198) | 1840 (290) | 1650 (132) | 1870 (191) |
42.9 (-37.2, 123) |
0.28 |
| Lysine | 2080 (156) | 2090 (171) | 2120 (169) | 2300 (384) |
66.5 (-17.7, 151) |
0.12 |
| Ornithine | 876 (134) | 798 (119) | 837 (146) | 841 (73.3) |
-8.05 (-51.7, 35.6) |
0.71 |
| Phenylalanine | 742 (115) | 747 (135) | 752 (70.9) | 824 (47.9) |
24.5 (-10.8, 59.8) |
0.16 |
| Proline | 2190 (601) | 2150 (567) | 2990 (1080) | 2480 (483) |
173 (-97, 443) |
0.20 |
| Serine | 1120 (114) | 1220 (183) | 1230 (253) | 1160 (248) |
16 (-56.8, 88.9) |
0.65 |
| Taurine | 700 (265) | 737 (57.5) | 611 (59.8) | 725 (113) |
-5.13 (-62.9, 52.6) |
0.86 |
| Threonine | 1490 (157) | 1520 (207) | 1590 (169) | 1500 (302) |
11.7 (-64.2, 87.7) |
0.75 |
| Tryptophan | 301 (64.8) | 315 (50.8) | 324 (44.1) | 350 (33.6) |
15.6 (-2.1, 33.2) |
0.081 |
| Tyrosine | 897 (160) | 845 (145) | 808 (117) | 927 (127) |
3.71 (-47.8, 55.3) |
0.88 |
| Valine | 3230 (265) | 3470 (335) | 3390 (233) | 3620 (200) |
110 (14.6, 205) |
0.026 |
| 3-methyl-histidine | 151 (71.2) | 104 (73.6) | 141 (72.8) | 120 (43) |
-6.07 (-31.6, 19.4) |
0.63 |
Discussion
In this secondary analysis of a dose-escalation study, we report that administration of increasing single doses of mesna, which effectively lowers plasma tCys (Vinknes et al. 2023), only minimally influences the remaining plasma amino acid pool and 3-methylhistidine. These findings indicate that there are few acute effects of mesna on amino acid metabolism. However, a drawback of the present study is that we were not able to quantify tissue concentrations or flux. In rodents, dietary restriction of cysteine alters plasma concentrations of histidine, phenylalanine, serine, threonine and tryptophan possibly by directing them to the TCA cycle (Gao et al. 2019; Nichenametla et al. 2022), with concomitant lower rates of protein synthesis, reduced growth rates and lower lean mass (Ables et al. 2012; Cooke and Ables 2023; Cooke et al. 2020). Therefore, long-term studies with mesna administration are needed to investigate whether our reported minor effects on the plasma amino acid pool persist over time, and whether there are negative effects on lean mass.
Although we mostly observed neutral effects of a single oral dose of mesna across different dose levels, there were indications of effects on branched-chain amino acids (BCAA). There was a significant increase in valine and a trend for an increase in isoleucine across dose levels. The underlying mechanism is unclear, but is likely indirect considering that mesna works by binding thiols in plasma and facilitate their urinary excretion. Speculatively, our results might relate to the effect of mesna on endogenous cysteine availability. Elimination of dietary cysteine rapidly induces autophagy in multiple experimental model systems (Cooke et al. 2020; Plummer and Johnson 2019; Ruckenstuhl et al. 2014) similar to short-term fasting (Shabkhizan et al. 2023). Notably, during 24 h of fasting in humans, plasma concentrations of BCAAs are elevated by ~ 14 to 38% with only negligible changes in other amino acids (Anfinsen et al. 2023). However, the study in question also reported the largest increase in plasma leucine, which we did not observe after ascending single doses of oral mesna. As such, we cannot exclude the possibility that the observed effect on valine and the weaker effect on isoleucine were due to chance.
This is the first study reporting on the acute effects of mesna on amino acids and 3-methylhistidine in humans with overweight and obesity. It provides preliminary, yet valuable information on whether mesna can affect the metabolism of other amino acids. Our study has clear limitations, including the small sample size, inclusion of men only, the short study duration, and the lack of a control group. In addition, the study was not designed to detect effects of mesna on the plasma or urine amino acid profile. These limitations impede the interpretation and generalizability of our findings. Thus, the results of this study are therefore mainly suitable to inform the planning and design of future studies, where these limitations can be overcome.
In conclusion, the acute effects of mesna on plasma and urinary concentrations of amino acids and 3-methylhistidine are minimal, but experimental and long-term human studies are needed to address whether repeated mesna dosing over time affects amino acid metabolism.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Acknowledgements
The authors would like to acknowledge the skilful assistance from the study nurses Edmar Augustin, Cristell Melby Magnussen, Kristin Sandnes and Merete Larsen Bjerke at the Clinical Research Unit at Oslo University Hospital, Rikshospitalet. We wish to thank Elisabeth Andrea Johnsen and Anja Falkenhaug Dahl for assistance with human sample handling. Finally, we also wish to thank all study participants for their time.
Author contributions
TO, AE, HR, KR, and KJV conceptualized and designed the study. TO, ES, HKZ, NEB and KJV collected data. TO was responsible for data analysis. TO drafted the manuscript. All authors contributed to interpretation of the results, review of the manuscript, and approval of the final version.
Funding
Open access funding provided by University of Oslo (incl Oslo University Hospital)
Data availability
The data are not publicly available due to privacy or ethical restrictions. Data can be requested from the corresponding author but is subject to ethical approvals and institutional collaboration agreements.
Declarations
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- Ables GP, Perrone CE, Orentreich D, Orentreich N (2012) Methionine-restricted c57bl/6j mice are resistant to diet-induced obesity and insulin resistance but have low bone density. PLoS ONE 7. 10.1371/JOURNAL.PONE.0051357 [DOI] [PMC free article] [PubMed]
- Anfinsen AM, Johannesen CO, Myklebust VH, Rosendahl-Riise H, McCann A, Nygard OK, Dierkes J, Lysne V (2023) Time-resolved concentrations of serum amino acids, one-carbon metabolites and b-vitamin biomarkers during the postprandial and fasting state: the postprandial metabolism in healthy young adults (pomet) study. Br J Nutr 1–15. 10.1017/S0007114523002490 [DOI] [PMC free article] [PubMed]
- Cooke D, Ables GP (2023) Physical activity of mice on dietary sulfur amino acid restriction is influenced by age of diet initiation and biological sex. Sci Rep 13(1):20609. 10.1038/s41598-023-47676-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cooke D, Mattocks D, Nichenametla SN, Anunciado-Koza RP, Koza RA, Ables GP, Anunciado-Koza RP, Koza RA, Ables GP (2020) Weight loss and concomitant adipose autophagy in methionine-restricted obese mice is not dependent on adiponectin or fgf21. Obes (Silver Spring) 28:1075–1085. 10.1002/oby.22763 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dong Z, Sinha R, Richie JP Jr. (2018) Disease prevention and delayed aging by dietary sulfur amino acid restriction: translational implications. Ann N Y Acad Sci 1418:44–55. 10.1111/nyas.13584 [DOI] [PubMed] [Google Scholar]
- Elshorbagy AK, Nurk E, Gjesdal CG, Tell GS, Ueland PM, Nygård O, Tverdal A, Vollset SE, Refsum H (2008) Homocysteine, cysteine, and body composition in the hordaland homocysteine study: does cysteine link amino acid and lipid metabolism? Am J Clin Nutr 88:738–746. 10.1093/ajcn/88.3.738 [DOI] [PubMed] [Google Scholar]
- Elshorbagy AK, Smith AD, Kozich V, Refsum H (2012) Cysteine and obesity. Obesity 20:473–481. 10.1038/oby.2011.93 [DOI] [PubMed] [Google Scholar]
- Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JP, Ciccarella A, Calcagnotto A, Mikhael PG, Mentch SJ, Liu J, Ables G, Kirsch DG, Hsu DS, Nichenametla SN, Locasale JW (2019) Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 572:397–401. 10.1038/s41586-019-1437-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hasek BE, Boudreau A, Shin J, Feng D, Hulver M, Van NT, Laque A, Stewart LK, Stone KP, Wanders D, Ghosh S, Pessin JE, Gettys TW (2013) Remodeling the integration of lipid metabolism between liver and adipose tissue by dietary methionine restriction in rats. Diabetes 62:3362–3372. 10.2337/db13-0501 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T (1994) Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35(2):132–136. 10.1007/BF00686635 [DOI] [PubMed] [Google Scholar]
- Malloy VL, Krajcik RA, Bailey SJ, Hristopoulos G, Plummer JD, Orentreich N (2006) Methionine restriction decreases visceral fat mass and preserves insulin action in aging male fischer 344 rats independent of energy restriction. Aging Cell 5:305–314. 10.1111/j.1474-9726.2006.00220.x [DOI] [PubMed] [Google Scholar]
- Malloy VL, Perrone CE, Mattocks DAL, Ables GP, Caliendo NS, Orentreich DS, Orentreich N (2013) Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice. Metab Clin Exp 62:1651–1661. 10.1016/j.metabol.2013.06.012 [DOI] [PubMed] [Google Scholar]
- Martinez W, Zhang Q, Linden MA, Schacher N, Darvish S, Mirek ET, Levy JL, Jonsson WO, Anthony TG, Hamilton KL (2022) Rates of protein synthesis are maintained in brain but reduced in skeletal muscle during dietary sulfur amino acid restriction. 10.3389/fragi.2022.975129 [DOI] [PMC free article] [PubMed]
- Nichenametla SN, Mattocks DAL, Malloy VL, Pinto JT (2018) Sulfur amino acid restriction-induced changes in redox-sensitive proteins are associated with slow protein synthesis rates. Ann N Y Acad Sci 1418:80–94. 10.1111/nyas.13556 [DOI] [PubMed] [Google Scholar]
- Nichenametla SN, Mattocks DAL, Cooke D, Midya V, Malloy VL, Mansilla W, Øvrebø B, Turner C, Bastani NE, Sokolová J, Pavlíková M, Richie JP, Shoveller AK, Refsum H, Olsen T, Vinknes KJ, Kožich V, Ables GP (2022) Cysteine restriction-specific effects of sulfur amino acid restriction on lipid metabolism. Aging Cell 2022.2005.2014.491847 10.1111/acel.13739 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olsen T, Stolt E, Ovrebo B, Elshorbagy A, Tore EC, Lee-Odegard S, Troensegaard H, Johannessen H, Doeland B, Vo AAD, Dahl AF, Svendsen K, Thoresen M, Refsum H, Rising R, Barvikova K, van Greevenbroek M, Kozich V, Retterstol K, Vinknes KJ (2024) Dietary sulfur amino acid restriction in humans with overweight and obesity: a translational randomized controlled trial. J Transl Med 22(1):40. 10.1186/s12967-023-04833-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- Plummer JD, Johnson JE (2019) Extension of cellular lifespan by methionine restriction involves alterations in central carbon metabolism and is mitophagy-dependent. Front Cell Dev Biology 7. 10.3389/FCELL.2019.00301/FULL [DOI] [PMC free article] [PubMed]
- Ruckenstuhl C, Netzberger C, Entfellner I, Carmona-Gutierrez D, Kickenweiz T, Stekovic S, Gleixner C, Schmid C, Klug L, Sorgo AG, Eisenberg T, Buttner S, Marino G, Koziel R, Jansen-Durr P, Frohlich KU, Kroemer G, Madeo F (2014) Lifespan extension by methionine restriction requires autophagy-dependent vacuolar acidification. PLoS Genet 10(5):e1004347. 10.1371/journal.pgen.1004347 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shabkhizan R, Haiaty S, Moslehian MS, Bazmani A, Sadeghsoltani F, Saghaei Bagheri H, Rahbarghazi R, Sakhinia E (2023) The beneficial and adverse effects of autophagic response to caloric restriction and fasting. Adv Nutr 14(5):1211–1225. 10.1016/j.advnut.2023.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stofer-Vogel B, Cerny T, Kupfer A, Junker E, Lauterburg BH (1993) Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br J Cancer 68(3):590–593. 10.1038/bjc.1993.391 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turner C, Refsum H, Bastani NE (2023) Determination of underivatized amino acids in human plasma using ion pair liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1229:123893. 10.1016/j.jchromb.2023.123893 [DOI] [PubMed] [Google Scholar]
- Urquhart BL, Freeman DJ, Spence JD, House AA (2007) Mesna as a nonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis. J Clin Pharmacol 47(8):991–997. 10.1177/0091270007303767 [DOI] [PubMed] [Google Scholar]
- Vinknes KJ, Olsen T, Zare HK, Bastani NE, Stolt E, Dahl AF, Cox RD, Refsum H, Retterstol K, Asberg A, Elshorbagy A (2023) Cysteine-lowering treatment with mesna against obesity: Proof of concept and results from a human phase i, dose-finding study. Diabetes Obes Metab 25(11):3161–3170. 10.1111/dom.15210 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data are not publicly available due to privacy or ethical restrictions. Data can be requested from the corresponding author but is subject to ethical approvals and institutional collaboration agreements.